At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...

If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.

Within the registrational trial, investigators will compare a single dose of 4D-150 to treatment with standard anti-VEGF therapy.

The bill's passage through the committee improves the rare pediatric disease priority review voucher program's chances of being reauthorized before it expires Sept. 30.

The center will conduct research and advance precision medicines for diabetes, pediatric rare diseases, cancer, and Alzheimer's disease.